• Pexidartinib (PLX3397): Precision CSF1R Inhibition in Cancer

  2026-05-20

  Pexidartinib (PLX3397) empowers researchers to dissect CSF1R-mediated signaling and modulate macrophage or microglial populations with high potency. This guide translates the latest mechanistic advances—including acute seizure models—into actionable protocols and troubleshooting strategies for tumor microenvironment and neuroinflammation workflows.

• XPO1 Inhibition by Eltanexor Modulates Wnt/β-catenin in CRC

  2026-05-20

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, effectively reduces colorectal cancer tumorigenesis by suppressing Wnt/β-catenin signaling and COX-2 expression. The findings highlight the translational potential of targeting nuclear export for chemoprevention in high-risk colorectal cancer models.

• RG7388 and the MDM1-p53 Axis: Advancing Translational Oncolo

  2026-05-19

  This thought-leadership article explores the mechanistic synergy between MDM2 antagonism and MDM1-mediated p53 pathway activation, focusing on RG7388’s unique translational value. Integrating recent biomarker discoveries, validated workflow strategies, and practical protocol guidance, it empowers cancer researchers to maximize the therapeutic and experimental impact of RG7388 in both preclinical and clinical settings.

• Decitabine (5-Aza-2'-deoxycytidine) in Solid Tumor Epigeneti

  2026-05-19

  Decitabine (5-Aza-2'-deoxycytidine) unlocks tumor suppressor gene reactivation through targeted DNA hypomethylation, offering a precise tool for dissecting cancer epigenetics in both hematopoietic and solid tumor models. This guide distills optimized workflows and troubleshooting strategies, leveraging recent breakthroughs in gastric cancer research to maximize reproducibility and data clarity.

• Oleanolic Acid: Breakthroughs in Dual-Loaded Liposome Encaps

  2026-05-18

  Discover how oleanolic acid enables high-efficiency dual-loaded liposome research through advanced encapsulation strategies and immune pathway modulation. This article uniquely distills method innovation and practical guidance for antiviral research.

• Pomalidomide (CC-4047): Precision Research for Myeloma Heter

  2026-05-18

  Explore how Pomalidomide (CC-4047) enables high-resolution insights into myeloma heterogeneity and resistance pathways. This article reveals advanced protocol strategies and practical implications for hematological malignancy research.

• NORFA lncRNA Regulates Estradiol Synthesis via SF-1/CYP11A1

  2026-05-17

  The study by Guo et al. uncovers the regulatory mechanism through which the long non-coding RNA NORFA enhances estradiol production and suppresses apoptosis in sow ovarian granulosa cells. By delineating the SF-1/CYP11A1 axis as a key mediator, the findings offer mechanistic insight into ovarian steroidogenesis and potential avenues for improving female fertility.

• EdU Flow Cytometry Assay Kits (Cy3) for Advanced Cell Cycle

  2026-05-16

  EdU Flow Cytometry Assay Kits (Cy3) deliver denaturation-free, multiplexed detection of cell proliferation and DNA synthesis, enabling high-content cell cycle analysis with superior workflow flexibility. APExBIO’s kit leverages click chemistry for reliable, quantitative S-phase assessment and supports integration with cell surface and intracellular markers for deeper biological insight.

• Ginkgo Biloba Compound Cocktail Boosts Yeast Mitochondrial L

  2026-05-15

  This study applies network pharmacology to identify and combine four Ginkgo biloba compounds into a defined cocktail that synergistically enhances mitochondrial function and extends lifespan in yeast. The findings provide mechanistic insight into phytochemical synergy for anti-aging intervention and inform protocol design for cellular metabolism research.

• MDM1 Overexpression Enhances p53-Mediated Therapy Sensitivit

  2026-05-15

  This study demonstrates that MDM1 overexpression increases p53 expression and apoptosis, enhancing chemoradiotherapy sensitivity in colorectal cancer (CRC) models. The findings identify MDM1 as a predictive biomarker for therapy response and clarify its mechanistic interplay with the p53 pathway, informing future translational oncology strategies.

• PCI-32765 (Ibrutinib): Precision BTK Inhibition for B-Cell a

  2026-05-14

  PCI-32765 (Ibrutinib) is revolutionizing B-cell and ATRX-deficient glioma research with its potent, selective BTK inhibition. This article details actionable protocol enhancements, troubleshooting guidance, and advanced applications—backed by recent reference findings and real-world workflows—to help researchers achieve reproducible, high-sensitivity results.

• MDM1-Mediated p53 Activation Enhances Chemoradiotherapy Resp

  2026-05-14

  This study reveals that MDM1 overexpression increases p53 expression and promotes apoptosis, thereby improving the sensitivity of colorectal cancer cells to chemoradiotherapy. These findings establish MDM1 as a predictive biomarker and mechanistic modulator of the p53 pathway in enhancing therapeutic outcomes.

• Cardiogreen (Indocyanine Green): Protocols and Innovations i

  2026-05-13

  Cardiogreen (Indocyanine Green) delivers unmatched precision in vascular diagnostics, hepatic function analysis, and photodynamic therapy. This article translates advanced experimental workflows and unique mechanistic insights into actionable protocols and troubleshooting strategies for researchers aiming to maximize reproducibility and translational impact.

• Syringin Natural Product: Optimizing RCC Research Workflows

  2026-05-13

  Harnessing the Syringin natural product streamlines bioactive compound screening and apoptosis research in renal cell carcinoma (RCC) by targeting the EGFR/PI3K/Akt pathway. This article delivers evidence-backed protocol enhancements, troubleshooting insights, and workflow optimizations that distinguish Syringin as a powerful research tool.

• Dovitinib (TKI-258): Multitargeted RTK Inhibition and Precis

  2026-05-12

  Explore how Dovitinib (TKI-258) drives apoptosis induction in cancer cells through multitargeted receptor tyrosine kinase inhibition. This article uniquely connects cutting-edge assay design with radiopathomics insights for translational oncology.

16785 records 1/1119 page Next 12345 下5页 Last page